Citra-Lock™ 4%

Citra-Lock 4% is recommended in the European Renal Best Practice
Guidelines (ERBP) and the American Society of Diagnostic and
Interventional Nephrology (ASDIN).

Citra locks have been extensively studied.
4% offers the best benefit/risk ratio.
Citra-Lock is effective in maintaining catheter patency.
Trisodium Citrate 4% (TSC) works as an anti-coagulant and decreases the
incidence of infection.

Clinical advantage of Citra-Lock 4% (compared to heparine)

• safe
• avoids heparin-associated bleeding
• improves reliability of INR assyas (prothrombin time – time/international
  normalised ratio)
• safe for heparin induced thrombocytopenia (HIT patients)
• no side effects
• reduction of tPA use
• better outcomes over catheter exchange
• reduction of hospitalisation
• cost efficient

Increase Safety & Simplified handling

The Citra-Lock vial features a drip free Luer-Slip/Luer-Lock connector

•  preventing microbial contamination
•  protecting against needle stick injuries
•  reducing handling steps
•  promoting intuitive handing
• Citra-Lock™ 4% 5ml vial
• Boxes contain 20 x 5ml vials
• Art. nr. :24060201

Brochure